Magellan Health (NASDAQ:MGLN) issued an update on its FY 2019 earnings guidance on Friday morning. The company provided EPS guidance of $3.70-4.69 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.50. The company issued revenue guidance of $7.2-7.5 billion, compared to the consensus revenue estimate of $7.11 billion.Magellan Health also updated its FY19 guidance to $3.70-4.69 EPS.
Several research analysts have weighed in on the company. TheStreet downgraded Magellan Health from a b- rating to a c+ rating in a research note on Friday, November 9th. BidaskClub downgraded Magellan Health from a strong-buy rating to a buy rating in a research report on Friday, August 31st. Zacks Investment Research downgraded Magellan Health from a hold rating to a sell rating in a research report on Saturday, October 13th. Leerink Swann downgraded Magellan Health from an outperform rating to a market perform rating and lowered their target price for the company from $90.00 to $70.00 in a research report on Tuesday, November 13th. Finally, ValuEngine downgraded Magellan Health from a sell rating to a strong sell rating in a research report on Tuesday, November 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $83.33.
NASDAQ:MGLN traded up $1.52 during midday trading on Friday, hitting $57.01. 6,999 shares of the company traded hands, compared to its average volume of 375,676. Magellan Health has a 12-month low of $51.88 and a 12-month high of $112.25. The firm has a market capitalization of $1.34 billion, a PE ratio of 10.36, a PEG ratio of 1.53 and a beta of 0.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 1.72.
Magellan Health (NASDAQ:MGLN) last released its quarterly earnings results on Wednesday, November 7th. The company reported $1.45 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.28. Magellan Health had a return on equity of 10.93% and a net margin of 1.49%. The company had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.85 billion. During the same quarter in the prior year, the firm posted $1.64 EPS. Magellan Health’s quarterly revenue was up 30.6% compared to the same quarter last year. Equities analysts forecast that Magellan Health will post 3.61 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/07/magellan-health-mgln-issues-fy-2019-earnings-guidance.html.
About Magellan Health
Magellan Health, Inc provides healthcare management services in the United States. It operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine for health plans, care organizations, and employers.
Recommended Story: Understanding Analyst Ratings
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.